Continuous ketone measurement got an FDA classification — a De Novo authorization for 'devices of a new type', with special controls, for diabetes and not for anything else (FDA, 25 Aug 2026)

Why it matters (spine). The garden's health spine keeps returning to one question: can you measure the thing you claim to be changing? This run's aging-clock card (epigenetic-clock-responsiveness-translage) is that question asked of a biomarker that needs a blood draw, a lab and a year. This is the same question answered at the other extreme — a biomarker sampled every minute, for ten days, on the arm, in a regulated device. Continuous glucose monitoring already reshaped how metabolic health is discussed, researched and sold. A second continuously measured metabolic analyte, arriving with an FDA classification behind it, is a change in what is instrumentable, and that is upstream of every intervention claim built on top of it.

What the FDA authorized. "The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes. The Libre Duo 10 Day is the first wearable device in the U.S. that continuously monitors ketone levels, and the first in the world to continuously monitor both ketones and blood sugar (glucose) together in a single device."

How it works, in the agency's words: the device "addresses that gap by continuously measuring both ketone and glucose levels in the fluid just beneath the skin, every minute, day and night. Readings are sent wirelessly to a compatible smartphone, where users can see their current ketone and glucose levels and whether they are trending up or down. The device can send automatic alerts if ketone levels reach a concerning threshold." And the caveat the FDA prints itself: "Ketone information should always be interpreted in the context of glucose readings and symptoms."

The evidence, as described. "The clinical program included data from six clinical studies that together enrolled more than 600 participants aged 2 years and older to evaluate the accuracy of the device's ketone and glucose monitoring functionality across a range of ketone and glucose levels. The results demonstrated that the device accurately tracked clinically meaningful differences in ketone levels across its 10-day wear period, including identifying elevated ketone levels before the onset of diabetic ketoacidosis." Note what that is: accuracy and detection studies, not an outcome trial. The FDA describes tracking and identification; it does not claim a reduction in ketoacidosis events, hospitalisations or deaths, and neither does this card.

The regulatory mechanics, which are the durable part. "The FDA granted marketing authorization to Abbott Diabetes Care for the Libre Duo 10 Day through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing special controls that define requirements including those related to labeling and performance testing. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness." The device also had Breakthrough Device designation before authorization, and the FDA situates the action within its "Home as a Health Care Hub" initiative, "which focuses on advancing the development of innovative, patient-centered devices that fit more seamlessly into people's daily lives at home."

De Novo matters more than the brand. The FDA's own words on the page are that it is "a regulatory pathway for low- to moderate-risk devices of a new type", and that its output here is "special controls that define requirements including those related to labeling and performance testing." That is the agency writing down what a continuous ketone monitor must demonstrate. Regulatory background, not from this page, and it covers more than one clause: De Novo is the route used when no suitable predicate device exists; the resulting classification is what later entrants can file a 510(k) against; and it is that mechanism, rather than anything the FDA page states, which turns one authorization into a reusable device category. None of that is described on the FDA page read here — the page says only "devices of a new type" and that special controls are being established. Wherever this card or its title speaks of a classification or a category, read it against this paragraph. What the page does support on its own is narrower and still useful: the agency has written down a labeling and performance-testing bar for a continuously-monitoring ketone device, which is more than a product launch.

Why it is verified, and what the tier does not cover. Provenance is a first-party FDA press announcement on fda.gov, dated inside the window, read from the main thread — so the claim this card makes, "the FDA authorized this device on this date with this indication on this evidence", is verified. Two things the tier explicitly does not vouch for. The priority claims ("first ... in the U.S.", "first in the world") are the FDA's assertions, quoted as such and not independently checked here. And the clinical value is unestablished by this document: an accuracy authorization says the sensor reads correctly, not that reading it changes outcomes.

Scope discipline, stated plainly because this is where the overreach will happen. The authorized population is "people aged 2 years and older living with diabetes." The epidemiology the FDA cites is "an estimated 40.1 million Americans" living with diabetes, of whom "an estimated 2.1 million Americans with type 1 diabetes" are the group for whom "blood sugar is only part of the picture." Nothing in this document authorizes, studies or supports use for ketogenic-diet adherence, intermittent fasting, exercise metabolism, weight management in non-diabetics, or any healthspan application. The garden's own hormesis-fasting-exercise-longevity-mechanism card sits exactly at this boundary — and note carefully what it says: it is held at trust_tier: signal because, in its words, the behaviours have "broad, independent evidence for metabolic and cardiovascular benefit" while the mechanistic story as told — sirtuins/AMPK, "this switches on your longevity genes and extends lifespan" — is "unproven." That card uses neither the phrase "metabolic switching" nor the word "ketone." So the adjacency here is not that the garden holds a mechanism a ketone sensor would confirm; it is that ketones are the readout a vendor would reach for in a space where the garden has already declined to endorse the mechanism. That is the exact configuration in which someone cites an FDA authorization for a use the FDA did not review, and this card is the document to hold up when it happens.

Where it sits against the cabinet. Read alongside epigenetic-clock-responsiveness-translage from four days earlier, the pair makes the run's sharpest point about measurement. The aging-clock paper's stated blocker is that no minimum clinically important difference exists for a DNA-methylation clock, so a clock change is not yet an outcome. Ketones have the opposite profile: a well-understood pathophysiology, an actionable threshold, an emergency to avert — and now a continuous sensor and a device classification. The instrumentable biomarkers and the ones with real interpretive frameworks are not the same set, and the longevity field mostly wants the intersection. Separately, the cabinet's GLP-1 cards (orforglipron-oral-glp1-fda-approval, an oral; semaglutide-cardiovascular-outcomes, dosed "weekly semaglutide 2.4 mg" in that card's words) describe interventions in the same physiology; a continuous dual-analyte sensor is the measurement layer those interventions would eventually be titrated against, though no document here says so.

Money angle and metacrisis lever. Money angle: the classification, not the sensor. A De Novo with special controls converts a one-vendor product into a market with a published bar, and it extends the continuous-monitoring business model to a second analyte — which for RDKG's purposes is a reminder that the durable value in a measurement category sits in the standard and the reference data, not the first device. Metacrisis lever: diabetic ketoacidosis is a fast, preventable, sometimes fatal complication, and the FDA's framing is that continuous ketone visibility can be "the difference between early intervention and a life-threatening emergency" — quoting Michelle Tarver, M.D., Ph.D., Director of the FDA's Center for Devices and Radiological Health, who called the authorization "a breakthrough for the safety of children and adults living with diabetes." Children aged 2 and up being inside the indication is the part of this that matters most and is easiest to skip past.

What would prove it wrong (falsifier). Three limbs.

• The authorization fails if the FDA rescinds or narrows it, or if the De Novo classification order and special controls as published differ from this description. The classification order itself was not opened for this card.
• The priority claims fail if a continuously-monitoring ketone wearable was authorized earlier in the US, or a dual ketone-glucose device anywhere — both are the FDA's words and neither was independently checked.
• The clinical promise fails if post-market data show the ketone channel is unreliable in real use, if alert thresholds produce alarm fatigue that degrades rather than improves ketoacidosis detection, or if a device-related adverse-event pattern appears. Accuracy across six studies and more than 600 participants is a pre-market standard; the honest test is post-market surveillance and, eventually, an outcome study nobody has run.

Provenance (what I actually read). The FDA press announcement "FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar", fetched from the main thread on 28 August 2026. The date is on the face of the page — "For Immediate Release: August 25, 2026" — corroborated by page metadata article:published_time: Tue, 08/25/2026 - 14:21, dcterms.contributor: Center for Devices and Radiological Health, and the footer "Content current as of: 08/25/2026". Every quotation and every figure above comes from that page, including the diabetes and type 1 prevalence figures, which the FDA attributes to the Centers for Disease Control and Prevention and which are quoted here as the FDA's citation of CDC rather than as CDC data I read. The only derived figure on this card is the four-day interval between the 21 August Nature Medicine paper and this 25 August authorization. I did not open the De Novo classification order, the device labeling, the special controls document, the summary of safety and effectiveness, the CDC data page, Abbott's press release or any Abbott filing, and no figure here comes from trade coverage. One passage is explicitly not from that page and is labelled where it appears: the sentence describing De Novo as the route used when no suitable predicate exists, and a resulting classification as something a later 510(k) can cite, is general regulatory background — the FDA page itself says only "a regulatory pathway for low- to moderate-risk devices of a new type." The two cross-referenced cards named above (hormesis-fasting-exercise-longevity-mechanism, semaglutide-cardiovascular-outcomes) were opened in the repository and their quoted language read directly — which is how the earlier draft's description of semaglutide as an oral was caught. One precision on that correction: the semaglutide card gives dose and frequency ("weekly semaglutide 2.4 mg") and does not state a route, so "injectable" above is background knowledge and not that card's word.